| Antares Pharma announced that it has completed enrollment in the double-blind portion of the ompancy's Phase III clinical trial of Anturol, its transdermal oxybutynin ATD gel for the treatment of overactive bladder. Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment FDA, is expected in the Q3 of this year. :theflyonthewall.com |
